These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22936806)

  • 1. Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells.
    Gupta V; Bhinge KN; Hosain SB; Xiong K; Gu X; Shi R; Ho MY; Khoo KH; Li SC; Li YT; Ambudkar SV; Jazwinski SM; Liu YY
    J Biol Chem; 2012 Oct; 287(44):37195-205. PubMed ID: 22936806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.
    Bhinge KN; Gupta V; Hosain SB; Satyanarayanajois SD; Meyer SA; Blaylock B; Zhang QJ; Liu YY
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1770-8. PubMed ID: 22728310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
    Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
    Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
    Liu YY; Hill RA; Li YT
    Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.
    Liu YY; Han TY; Giuliano AE; Cabot MC
    J Biol Chem; 1999 Jan; 274(2):1140-6. PubMed ID: 9873062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
    Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
    J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line.
    Moreira MP; Franco EP; Barros BAF; Anjos BRD; Almada DG; Barbosa INT; Braga LDC; Cassali GD; Silva LM
    Biochem Biophys Res Commun; 2024 Nov; 734():150765. PubMed ID: 39357337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
    Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
    J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
    Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
    Ma X; Zhang Y; Kang Y; Li L; Zheng W
    Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.
    Lin QY; Wang JQ; Wu LL; Zheng WE; Chen PR
    Breast Cancer; 2020 Jan; 27(1):147-158. PubMed ID: 31410735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47.
    Tan W; Tang H; Jiang X; Ye F; Huang L; Shi D; Li L; Huang X; Li L; Xie X; Xie X
    J Cell Mol Med; 2019 Sep; 23(9):5994-6004. PubMed ID: 31273952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
    Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
    Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
    Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
    Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
    Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
    Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
    Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
    McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
    Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.